Laennec inj.

Product Overview

LAENNEC Inj. is a prescription injectable pharmaceutical product containing human placenta hydrolysate. The South Korean formulation is manufactured and marketed by GC Wellbeing Co., Ltd. and is supplied as a light yellowish-brown to yellowish-brown solution in 2 mL amber glass ampoules. LAENNEC is indicated for the improvement of liver function in patients with chronic liver disease.

Human placenta hydrolysate is a complex biological preparation derived from processed human placental tissue. It contains water-soluble substances, including peptides, amino acids, and other components resulting from the hydrolysis process. Unlike single-molecule pharmaceuticals, its pharmacological characteristics cannot be attributed to one isolated active compound.

LAENNEC originated from Japan Bio Products Co., Ltd. (JBP), which also markets a Japanese prescription formulation under the same brand name. The Korean product is registered under GC Wellbeing, and its specifications and regulatory documentation should be evaluated separately from the Japanese presentation.

This page provides professional buyers with information about LAENNEC's active ingredient, ampoule presentation, approved indication, storage requirements, and regulatory considerations. The product is a prescription medicine rather than a conventional cosmetic skin booster.

Key Features

• Human Placenta Hydrolysate: Contains a processed human placental preparation composed of water-soluble biological substances, including peptides and amino acids.
• Liver Function Improvement: The approved indication in South Korea is improvement of hepatic function in patients with chronic liver disease.
• 2 mL Ampoule Presentation: Supplied as a ready-to-use liquid pharmaceutical formulation in individual 2 mL amber glass ampoules.
• Documented Clinical Evaluation: Human placenta hydrolysate preparations marketed as LAENNEC have been evaluated in clinical studies involving chronic liver disease and liver enzyme measurements.
• South Korean Prescription Product: LAENNEC Inj. is registered in South Korea as a prescription medicine under GC Wellbeing Co., Ltd.

Composition & Specifications

The active ingredient in LAENNEC Inj. is human placenta hydrolysate, also known as hydrolyzed human placental extract. The following specifications primarily describe the South Korean product registered under GC Wellbeing.

Human Placenta Hydrolysate

Human placenta hydrolysate is produced through controlled processing and hydrolysis of human placental tissue. Hydrolysis breaks down larger biological structures into smaller water-soluble components, producing a complex mixture that may include peptides, amino acids, and other low-molecular-weight substances.

Because the preparation contains multiple biological components, the complete pharmacological contribution of each constituent has not been independently established.

Japanese LAENNEC Composition

The Japanese LAENNEC formulation manufactured by Japan Bio Products contains 112 mg of water-soluble human placenta hydrolysate per 2 mL ampoule. Its published specifications also describe the use of a pH-adjusting agent.

The South Korean product declaration expresses the active ingredient as 2 mL of human placenta hydrolysate per 2 mL ampoule. The Japanese 112 mg specification should not automatically be assigned to the Korean product without confirming the corresponding manufacturing and analytical documentation.

LAENNEC is marketed in more than one jurisdiction. Manufacturer identity, quantitative labeling, packaging, and registration details must be checked against the specific product presentation supplied.

How LAENNEC Works

LAENNEC contains a complex mixture of substances derived from hydrolyzed human placenta. Unlike medicines containing a single chemically defined active compound, the pharmacological activity of human placenta hydrolysate cannot be attributed to one specific molecular mechanism.

Hepatic Function and Tissue Response

The liver plays a central role in metabolism, detoxification, protein synthesis, and nutrient processing. Liver injury can produce changes in biochemical markers such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Experimental research involving LAENNEC has investigated hepatocyte activity, cellular DNA synthesis, and biochemical responses associated with liver injury. Animal and laboratory studies have reported changes in liver regeneration-related processes and selected markers of hepatic damage.

Clinical Evidence in Chronic Liver Disease

Clinical studies have evaluated LAENNEC in patients with chronic liver disease. A Japanese double-blind crossover study involving 124 patients with chronic hepatitis or liver cirrhosis reported improvements in serum transaminase measurements.

South Korean clinical reevaluation has also examined LAENNEC in patients with alcoholic hepatitis or nonalcoholic steatohepatitis using liver enzyme outcomes.

These findings relate to hepatic function and should not be interpreted as clinical evidence for anti-aging, skin rejuvenation, immune enhancement, fatigue recovery, or other unapproved aesthetic and wellness applications.

The complete pharmacokinetic profile of LAENNEC has not been established because its biological activity cannot be assigned to a single identifiable active substance.

Packaging & Product Presentation

LAENNEC Inj. is supplied as a transparent liquid in amber glass ampoules. Each ampoule contains 2 mL of human placenta hydrolysate solution.

GC Wellbeing documents 10-, 25-, and 50-ampoule packaging configurations for the Korean product. Japan Bio Products documents 10- and 50-ampoule boxes for its Japanese presentation.

The listed box configurations describe manufacturer-documented packaging and do not establish the specific selling unit, stock status, or supply conditions of an individual TEOSQUARE listing.

Confirm the country-specific package, original manufacturer labeling, expiration date, batch number, and applicable regulatory documentation before procurement.

Storage & Handling

The South Korean manufacturer specifies storage at controlled room temperature between 1°C and 30°C in light-protected, tightly closed containers.

• Storage Temperature: Store at 1°C to 30°C according to the Korean product labeling.
• Light Protection: Maintain the product in its original light-protected packaging.
• Container Integrity: Inspect ampoules for cracks, damage, or other signs of compromised packaging.
• Single-Use Presentation: Follow the official product instructions for opening, handling, and disposal of glass ampoules.
• Traceability: Verify the manufacturing lot, expiration date, and market-specific product information.

Storage conditions should be confirmed against the supplied manufacturer's labeling. Do not assume that requirements for the Korean and Japanese commercial presentations are identical.

Safety & Regulatory Considerations

LAENNEC Inj. is a prescription pharmaceutical product derived from human placental tissue. Its use requires appropriate medical supervision, evaluation of treatment necessity, and compliance with local prescribing and distribution regulations.

Human-Derived Biological Material

The production of human placenta-derived medicines involves donor screening, infectious disease testing, and manufacturing controls designed to reduce the risk of transmitting infectious agents.

Despite these measures, the potential transmission of infectious agents from human-derived starting materials cannot be eliminated completely. Product-specific safety documentation should be reviewed before clinical use.

Adverse Reactions

Reported adverse reactions associated with LAENNEC include injection-site pain, redness, induration, fever, rash, itching, and other hypersensitivity reactions. Serious allergic reactions, including shock, are possible.

The product is contraindicated in patients with known hypersensitivity to its components. Additional precautions apply to individuals with allergic predispositions and other patient-specific risk factors.

Regulatory Indications

The approved indication for LAENNEC in South Korea and Japan is improvement of liver function in chronic liver disease.

LAENNEC should not be represented as an approved injectable skin booster, anti-aging treatment, cosmetic rejuvenation product, or general wellness injection solely because human placenta-derived ingredients have been investigated for other biological activities.

Regulatory authorization in South Korea or Japan does not automatically establish approval in other jurisdictions. Professional buyers must independently verify local drug registration, import eligibility, prescribing restrictions, and permitted distribution channels.

Japan Bio Products explicitly states that it does not sell LAENNEC Injection through internet retail channels. Any commercial sourcing arrangement must independently establish lawful supply and applicable distribution authorization. This page is intended for professional product identification and regulatory comparison, not unrestricted online purchasing.

Frequently Asked Questions